Alyson Thank you so very much for flagging this up. I really did not have a clue this was in the recommendations, the documentation is just beyond my comprehension!
(Quote from Alysons post below)
'Having studied the latest NICE ACD in order to submit comments by yesterday's deadline. I was horrified to discover that the 'concession' for existing Dasatinib/Nilotinib patients to be able to continue treatment (which had been included in the first ACD in November) has now been removed!'
Sandy can you please, please, let those of us who find this all very very difficult to untangle, the possible timeline of events and the possible/potential actions to be taken? Perhaps a brief overview of the future actions would be extremely helpful.
Many thanks
Pennie.